COX-2 overexpression has been described in ectopic endometriosis implants when compared with eutopic endometrium [23], in endometrial carcinoma where it is associated with several parameters of tumor aggressiveness [24,25], and in endometriosis-associated ovarian carcinoma [26]. Here, PTGS2 is linked to ovarian carcinoma.